This report provides data on the therapeutic development for T-Cell Lymphomas, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for T-Cell Lymphomas. 'T-Cell Lymphomas - Pipeline Review, H1 2012' is built using data and information sourced from Global Industries Direct’s proprietary databases, Firms /University websites, SEC filings, investor presentations and featured press releases from firm /university sites and market -specific third party sources, put together by Global Industries Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.



Scope of the Research


- A snapshot of the global therapeutic scenario for T-Cell Lymphomas.
- A review of the T-Cell Lymphomas products under development by industry players and universities/research institutes based on information derived from industry player and market -specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the T-Cell Lymphomas pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage new product development featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.



Reasons to buy


- Identify and understand important and diverse types of therapeutics under development for T-Cell Lymphomas.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and take over s effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding T-Cell Lymphomas pipeline depth and focus of T-Cell Lymphomas therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and grow business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Table of Contents
Data table of Contents 2
List of Tables 5
List of Figures 6
Introduction 8
Global March kets Direct Report Coverage 8
T-Cell Lymphomas Overview 9
Therapeutics Development 10
An Overview of Pipeline Products for T-Cell Lymphomas 10
T-Cell Lymphomas Therapeutics under Development by Firms 12
T-Cell Lymphomas Therapeutics under Investigation by Universities/Institutes 15
Late Stage Products 19
Comparative Analysis 19
Mid Clinical Stage Products 20
Comparative Analysis 20
Early Clinical Stage Products 21
Comparative Analysis 21
Discovery and Pre-Clinical Stage Products 22
Comparative Analysis 22
T-Cell Lymphomas Therapeutics - Products under Development by Firms 23
T-Cell Lymphomas Therapeutics - Products under Investigation by Universities/Institutes 25
Companies Involved in T-Cell Lymphomas Therapeutics Development 29
Kyowa Hakko Kirin Co., Ltd. 29
Abbott Laboratories 30
Amgen Inc. 31
Seattle Genetics, Inc. 32
Emergent BioSolutions Inc. 33
ZIOPHARM Oncology, Inc. 34
Millennium Pharmaceuticals, Inc. 35
Cephalon, Inc. 36
Eisai Co., Ltd. 37
Celgene Corporation 38
Incyte Corporation 39
Allos Therapeutics, Inc 40
BioCryst Pharmaceuticals, Inc. 41
TopoTarget A/S 42
Pharmacyclics, Inc. 43
Sareum Holdings plc 44
Chipscreen Biosciences Ltd 45
Xencor, Inc. 46
PharmaMarch, S.A. 47
T-Cell Lymphomas - Therapeutics Assessment 48
Assessment by Monotherapy Products 48
Assessment by Combination Products 49
Assessment by Route of Administration 50
Assessment by Molecule Type 52
Drug Profiles 55
ABT-263 - Drug Profile 55
MLN8237 - Drug Profile 57
Adcetris - Drug Profile 59
Adcetris - Drug Profile 62
Chidamide - Drug Profile 65
Belinostat - Drug Profile 66
KW-0761 - Drug Profile 68
PCI-34051 - Drug Profile 70
Jakafi - Drug Profile 71
Forodesine - Drug Profile 73
Zinapar - Drug Profile 75
Ontak - Drug Profile 77
Folotyn - Drug Profile 79
XmAb2513 - Drug Profile 82
Zanolimumab - Drug Profile 83
Aplidin - Drug Profile 84
Lenalidomide - Drug Profile 85
Revlimid + Zolinza + Dexamethasone - Drug Profile 86
Clofarabine - Drug Profile 87
Poly-ICLC + Low Dose Local Radiation - Drug Profile 88
Campath-1H + CHOP - Drug Profile 89
Alemtuzumab + CHOP + ESHAP - Drug Profile 91
CHOP-14 + Alemtuzumab - Drug Profile 93
C-CHOP - Drug Profile 95
Romidepsin - Drug Profile 97
Vorinostat + Azacitidine - Drug Profile 99
Dexamethasone + Ifosfamide + Cisplatin + Etoposide - Drug Profile 100
Folotyn + Gemcitabine Hydrochloride - Drug Profile 101
SGN-35 + Rifampin - Drug Profile 102
SGN-35 + Ketoconazole - Drug Profile 104
Revlimid - Drug Profile 105
Lenalidomide + Vorinostat + Dexamethasone - Drug Profile 107
Rituximab + Siplizumab + Cyclophosphamide + Doxorubicin + Etoposide + Prednisone + Vincristine + Filgrastim - Drug Profile 108
CHOP14 + G-CSF + MabCampath + Autologous Stem Cell Transplantation - Drug Profile 111
UCN-01 - Drug Profile 113
Fludarabine + Doxorubicin + Dexamethasone - Drug Profile 114
Asparaginase + Cyclophosphamide + Cytarabine + Daunorubicin Hydrochloride + Dexamethasone + Etoposide + Mercaptopurine + Methotrexate + Methylprednisolone + Mitoxantrone Hydrochloride + Prednisone + Vincristine Sulfate + Radiation Therapy - Drug Profile 115
Roferon + Accutane - Drug Profile 118
Zolinza + CHOP - Drug Profile 119
RAD001 + Revlimid - Drug Profile 121
Busulfan + Cyclophosphamide + Etoposide + Radiation Therapy + Bone March row Transplantation - Drug Profile 122
Cisplatin + Etoposide + Gemcitabine + Solumedrol - Drug Profile 124
Cyclophosphamide + Etoposide + Allogeneic Bone March row Transplantation + Radiation Therapy - Drug Profile 126
Cyclophosphamide + Hydroxydaunorubicin + Vincristine + Prednisone + G-CSF + Alemtuzumab - Drug Profile 128
Etoposide + Vincristine + Doxorubicin + Prednisone + Cyclophosphamide + Bortezomib + Raltegravir - Drug Profile 130
L-Asparaginase + Methotrexate + Dexamethasone - Drug Profile 133
HCVIDDOXIL + Methotrexate + Ara-C - Drug Profile 135
Bendamustine - Drug Profile 137
MEDI-507 - Drug Profile 138
Treanda + Carboplatin + Rituximab + Etoposide - Drug Profile 139
Nelfinavir + Bortezomib - Drug Profile 141
Ara-C + Cyclophosphamide + Fludarabine + Busulfan + Total Body Irradiation + Cord Blood Transplantation - Drug Profile 142
Etoposide + Doxorubicin + Vincristine + Cyclophosphamide + Prednisolone - Drug Profile 144
Istodax - Drug Profile 146
RAD001 + CHOP - Drug Profile 147
Busulfan + Cyclophosphamide + Allogeneic Bone March row Transplantation + Methylprednisolone + Methotrexate + Cyclosporine - Drug Profile 149
SMILE - Drug Profile 151
Lenalidomide + Rituximab + Carmustine + Etoposide + Cytarabine + Melphalan + Autologous Hematopoietic Stem Cell Transplant - Drug Profile 153
IMTOX25 - Drug Profile 156
Etoposide + Prednisone + Vincristine + Cyclophosphamide + Doxorubicin + Lamivudine + Zidovudine + Interferon Alfa - Drug Profile 157
Endostar + CHOP - Drug Profile 160
CHOEP + G-CSF + BEAM - Drug Profile 162
Carmustine + Etoposide + Cytarabine + Fludarabine Phosphate + Cyclophosphamide + Tacrolimus + Mycophenolate Mofetil + Melphalan + Filgrastim + Stem Cell Transplantation + Radiation Therapy - Drug Profile 164
Cyclophosphamide + Cytarabine + Dexamethasone + Doxorubicin + Etoposide + Ifosfamide + Leucovorin Calcium + Methotrexate + Therapeutic Hydrocortisone + Vinblastine - Drug Profile 167
CHOP + Campath-1H - Drug Profile 171
Campath-1H + Cyclophosphamide + Doxorubicin Hydrochloride + Etoposide + Prednisone + Vincristine Sulfate - Drug Profile 172
Nelarabine + Etoposide + Cyclophosphamide + Methotrexate + Filgrastim - Drug Profile 174
Amevive - Drug Profile 176
Vidaza + Velcade - Drug Profile 177
PF02341066 - Drug Profile 178
Busulfan + Etoposide + Cyclophosphamide + Fludarabine + Mesna + Phenytoin + Ursodiol + Autologous Peripheral Blood Stem Cells + Neupogen + Allogenic Peripheral Blood Stem Cell Transplant + Tacrolimus + Sirolimus + Methotrexate - Drug Profile 179
FK228 - Drug Profile 182
Gemcitabine + Navelbine + Doxil + G-CSF + Cyclophosphamide + Vincristine + Prednisone + Autologous Stem Cell Transplantation + Ontak - Drug Profile 183
CEP-37440 - Drug Profile 185
Istodax + CHOP - Drug Profile 186
Fludarabine + Cytarabine + Busulfan/Melphalan+ Antithymocyte Globulin + Cyclophosphamide + Tacrolimus + Mycophenolate Mofetil + Stem Cell Transplantation - Drug Profile 188
SGN-35 + Cyclophosphamide + Prednisone + Doxorubicin + Vincristine - Drug Profile 191
AMG 319 - Drug Profile 193
Aurora + ALK Program - Drug Profile 194
Carfilzomib - Drug Profile 195
Cisplatin + L-Asparaginase + Methotrexate + Ifosfamide + Dexamethasone + Etoposide + Radiation Therapy - Drug Profile 196
SGN-35 + Cyclophosphamide + Prednisone + Doxorubicin - Drug Profile 198
Allogeneic Hematopoietic Stem Cell Transplantation - Drug Profile 200
Bortezomib - Drug Profile 201
Bone March row Transplantation - Drug Profile 202
Peripheral Blood Stem Cell Transplantation - Drug Profile 203
IMTOX-25 - Drug Profile 204
KW-0761 + mLSG15 - Drug Profile 205
LBH589 - Drug Profile 208
Alemtuzumab + Fludarabine + Cyclophosphamide + Doxorubicin - Drug Profile 209
T-Cell Lymphomas Therapeutics - Drug Profile Updates 211
T-Cell Lymphomas Therapeutics - Discontinued Products 241
T-Cell Lymphomas Therapeutics - Dormant Products 242
T-Cell Lymphomas - Product Development Milestones 246
Featured News and Press Releases 246
Appendix 255
Methodology 255
Coverage 255
Secondary Research 255
Primary Research 255
Expert Panel Validation 255
Contact Us 256
Disclaimer 256

List of Tables

Number of Products Under Development for T-Cell Lymphomas, H1 2012 16
Products under Development for T-Cell Lymphomas - Comparative Analysis, H1 2012 17
Number of Products under Development by Firms, H1 2012 19
Number of Products under Development by Firms, H1 2012 (Contd..1) 20
Number of Products under Investigation by Universities/Institutes, H1 2012 22
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..1) 23
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..2) 24
Comparative Analysis by Late Stage Development, H1 2012 25
Comparative Analysis by Mid Clinical Stage Development, H1 2012 26
Comparative Analysis by Early Clinical Stage Development, H1 2012 27
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2012 28
Products under Development by Firms, H1 2012 29
Products under Development by Firms, H1 2012 (Contd..1) 30
Products under Investigation by Universities/Institutes, H1 2012 31
Products under Investigation by Universities/Institutes, H1 2012 (Contd..1) 32
Products under Investigation by Universities/Institutes, H1 2012 (Contd..2) 33
Products under Investigation by Universities/Institutes, H1 2012 (Contd..3) 34
Kyowa Hakko Kirin Co., Ltd., H1 2012 35
Abbott Laboratories, H1 2012 36
Amgen Inc., H1 2012 37
Seattle Genetics, Inc., H1 2012 38
Emergent BioSolutions Inc., H1 2012 39
ZIOPHARM Oncology, Inc., H1 2012 40
Millennium Pharmaceuticals, Inc., H1 2012 41
Cephalon, Inc., H1 2012 42
Eisai Co., Ltd., H1 2012 43
Celgene Corporation, H1 2012 44
Incyte Corporation, H1 2012 45
Allos Therapeutics, Inc, H1 2012 46
BioCryst Pharmaceuticals, Inc., H1 2012 47
TopoTarget A/S, H1 2012 48
Pharmacyclics, Inc., H1 2012 49
Sareum Holdings plc, H1 2012 50
Chipscreen Biosciences Ltd, H1 2012 51
Xencor, Inc., H1 2012 52
PharmaMarch, S.A., H1 2012 53
Assessment by Monotherapy Products, H1 2012 54
Assessment by Combination Products, H1 2012 55
Assessment by Stage and Route of Administration, H1 2012 57
Assessment by Stage and Molecule Type, H1 2012 60
T-Cell Lymphomas Therapeutics - Drug Profile Updates 216
T-Cell Lymphomas Therapeutics - Discontinued Products 246
T-Cell Lymphomas Therapeutics - Dormant Products 247
T-Cell Lymphomas Therapeutics - Dormant Products (Contd..1) 248
T-Cell Lymphomas Therapeutics - Dormant Products (Contd..2) 249
T-Cell Lymphomas Therapeutics - Dormant Products (Contd..3) 250

List of Figures

Number of Products under Development for T-Cell Lymphomas, H1 2012 16
Products under Development for T-Cell Lymphomas - Comparative Analysis, H1 2012 17
Products under Development by Firms, H1 2012 18
Products under Investigation by Universities/Institutes, H1 2012 21
Late Stage Products, H1 2012 25
Mid Clinical Stage Products, H1 2012 26
Early Clinical Stage Products, H1 2012 27
Discovery and Pre-Clinical Stage Products, H1 2012 28
Assessment by Monotherapy Products, H1 2012 54
Assessment by Combination Products, H1 2012 55
Assessment by Route of Administration, H1 2012 56
Assessment by Stage and Route of Administration, H1 2012 57
Assessment by Molecule Type, H1 2012 58
Assessment by Stage and Molecule Type, H1 2012 59

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers

Drug and Medication Industry: Prostate Cancer – Pipeline Review, H1 2012

Drug and Medication Industry: Prostate Cancer – Pipeline Review, H1 2012

  • $ 2 500
  • Company report
  • June 2014
  • by Global Markets Direct

This report provides data on the therapeutic development for Prostate Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved ...

Pathology in United States: Fatty Liver Disease – Pipeline Review, H1 2012

Pathology in United States: Fatty Liver Disease – Pipeline Review, H1 2012

  • $ 2 000
  • Company report
  • April 2014
  • by Global Markets Direct

This report provides data on the therapeutic development for Fatty Liver Disease, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players ...

Pathology Industry: Depression – Pipeline Review, H1 2012

Pathology Industry: Depression – Pipeline Review, H1 2012

  • $ 2 000
  • Company report
  • April 2014
  • by Global Markets Direct

This report provides data on the therapeutic development for Depression, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved ...


ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.